[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"high-cholesterolhyperlipidemia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:high-cholesterolhyperlipidemia":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,55,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":32,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100592056","pilot-study-of-bottarga-supplementation-a-little-known-sustainable-blue-food-100592056",false,"NCT06988462","Pilot Study of \"Bottarga\" Supplementation: A Little-known, Sustainable \"Blue\" Food","* Adults aged 18-60 years\n* Residents of Massachusetts\n* Presence of at least one metabolic abnormality (low HDL cholesterol, elevated LDL cholesterol, elevated triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes\n* Not pregnant\n* Willing to consume a nutritional supplement and comply with study procedures\n\nExclusion Criteria:\n\n* Use of any medications for diabetes (except metformin), dyslipidemia (except statins), or immunosuppression\n* Current use of any supplements containing n-3 fatty acids\n* Current use of illicit drugs (other than marijuana)\n* Use of hormone therapy (except oral contraceptives)\n* Known allergies to fish, seafood, or any fish-derived products, including bottarga\n* Pregnancy\n* Clinical evidence or history of hepatic or renal insufficiency\n* Immunodeficiency conditions\n* History of non-skin cancer\n* Participation in other clinical research studies","ALL","18 Years","60 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"NA","This pilot study aims to explore the potential benefits of consuming Greek bottarga (grey mullet fish roe) in individuals with at least one metabolic abnormality (low HDL cholesterol, high LDL cholesterol, high triglycerides, obesity, or HbA1c ≥ 5.7%) or a diagnosis of diabetes.\n\nBefore initiating the crossover randomized controlled trial (RCT), the investigators will conduct a preliminary dose-testing study in five adults with at least one metabolic abnormality. Participants will undergo clinical assessments before and after the dietary intervention to evaluate changes in metabolic health markers. Following this phase, the investigators will proceed with a randomized, controlled crossover trial involving 20 eligible adult participants. This main study phase will compare the metabolic effects of daily bottarga supplementation with those of a calorically matched dairy product over an 8-week intervention period, with a 2-week washout period between interventions.\n\nThe investigators anticipate that bottarga supplementation will improve lipid profiles, inflammation markers, and insulin resistance, thereby supporting the potential use of sustainable blue foods as part of a healthy diet.",[26,27,28,29,30,31],"Prediabetes","Diabetes","High Cholesterol\u002FHyperlipidemia","Obesity & Overweight","Triglycerides","HDL Cholesterol",[33,34,35,36,37,38,39,40,41],"Bottarga","pre diabetes","inflammation","sustainability","nutritional intervention","overweight","metabolic abnormalities","lipid profile","diabetes","RECRUITING","2026-02-17",{"date":45,"type":46},"2026-02-19","ACTUAL",{"date":48,"type":46},"2025-10-17",{"date":50,"type":20},"2026-12-01",{"name":52,"class":53},"Cambridge Health Alliance","OTHER",1,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":11,"sex":15,"minAge":16,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":21,"phases":65,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100544852","pharmacy-led-transitions-of-care-intervention-to-improve-medication-adherence-100544852","NCT06374277","Pharmacy-led Transitions of Care Intervention to Improve Medication Adherence","Pharmacy-led Transitions of Care Intervention to Address System-Level Barriers and Improve Medication Adherence in Socioeconomically Disadvantaged Populations","MedAAAction","Inclusion Criteria:\n\n* Medicaid or uninsured inpatients\n* 21 years or older\n* ≥2 of the complex chronic conditions during index admission or prescribed\u002Fusing ≥2 chronic medications for these conditions\n* Patients receiving chronic disease medications from the hospital pharmacy.\n* Patients will be eligible if they have multiple complex chronic conditions including diabetes, hypertension, high cholesterol, coronary artery disease, congestive heart failure, chronic lung disease, chronic kidney disease, arrhythmia, stroke, psychiatric disorders including depression and anxiety, or who are prescribed or using anticoagulants.\n\nExclusion Criteria:\n\n* Medicare and Medicaid dual eligible patients.\n* If the primary reason for the index admission is related to cancer, pregnancy, or a surgical procedure for an acute problem\n* If patients have diagnoses of active psychosis, substance abuse, or suicidal ideation during the index admission.\n* If the planned discharge location is not home.\n* If patients are part of an existing pharmacy discharge program.",{"count":64,"type":20},388,[23],"Socioeconomically disadvantaged populations with multiple chronic conditions have high rates of nonadherence to essential chronic disease medications after hospital discharge. Medication nonadherence after hospital discharge is significantly associated with increased mortality and higher rates of readmissions and costs among these patients. Major patient-reported barriers to essential medication use after hospital discharge among low-income individuals are related to social determinants of health (SDOH) and include: 1) financial barriers , 2) transportation barriers, and 3) system-level barriers. Although, medication therapy management services are important during care transitions, these services have not proven effective in improving medication adherence after hospital discharge, highlighting a critical need for innovative interventions. The Medication Affordability, Accessibility, and Availability in Care Transitions (Med AAAction) Study will test the effectiveness of a pharmacy-led care transitions intervention versus usual care through a pragmatic randomized controlled trial of 388 Medicaid and uninsured hospital in-patients with MCC from three large healthcare systems in Tennessee. The intervention will involve: 1) medications with zero copay, 2) bedside delivery then home delivery of medications, and 3) care coordination provided by certified pharmacy technicians\u002Fhealth coaches to assist with medication access, medication reconciliation, and rapid and ongoing primary care follow-up. We will examine the impact of the intervention during 12 months on 1) medication adherence (primary outcome) and 2) rapid primary care follow-up, 30-day readmissions, hospitalizations and emergency department visits, and costs. We will conduct key informant interviews to understand patient experience with the acre received during and after care transitions. By examining effectiveness of the intervention on outcomes including medication adherence, health care utilization, costs, and patient experience, this study will provide valuable results to health systems, payers, and policymakers to assist in future implementation and sustainability of the intervention for socioeconomically disadvantaged populations.",[27,68,28,69,70,71,72,73,74,75,76,77,78],"Hypertension","Coronary Artery Disease","Congestive Heart Failure","Chronic Lung Disease","Chronic Kidney Diseases","Arrythmia","Stroke","Depression","Anxiety","Pulmonary Embolism","Heart Attack","2026-01-27",{"date":81,"type":46},"2026-01-29",{"date":83,"type":46},"2024-04-06",{"date":85,"type":20},"2028-01-31",{"name":87,"class":53},"University of Tennessee",2,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":93,"acronym":4,"eligibilityCriteria":94,"healthyVolunteers":11,"sex":95,"minAge":16,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":21,"phases":98,"briefSummary":99,"conditions":100,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":54},"100609871","fellaship-to-better-health-100609871","NCT07220213","FELLAShip to Better Health","Inclusion Criteria:\n\n* Self-identified Black men\n* Age 18 or older\n* LE8 (Life's Essential 8) score (threshold not specified, but implies \"less than ideal\" CVH)\n* English speaking\n* Resides in the Metropolitan Birmingham, Alabama area\n* No physical activity restrictions imposed by a healthcare provider\n\nExclusion Criteria:\n\n* Not identifying as Black and male\n* Under age 18\n* Non-English speakers\n* Not living in the Birmingham, Alabama metro area\n* Having a healthcare provider-imposed restriction on physical activity\n* Ideal CVH (i.e., LE8 (Life's Essential 8) score above inclusion threshold)","MALE",{"count":97,"type":20},90,[23],"The goal of this clinical trial is to evaluate the implementation and effectiveness of the FELLAship program-a church-based cardiovascular health (CVH) intervention-in Black men aged 35-70 who are at risk for heart disease, diabetes, obesity, and related conditions. The main questions this study aims to answer are:\n\n* Does participation in the FELLAship program improve cardiovascular health metrics (e.g., blood pressure, cholesterol, blood sugar) and health behaviors among Black men at The Worship Center Christian Church (TWC)?\n* What factors influence the adoption, delivery, and sustainability of the FELLAship program in a faith-based setting? Researchers will compare an immediate-start intervention group and a delayed-start (waitlist control) group to assess both short-term health outcomes and program implementation factors.\n\nParticipants will:\n\n* Attend a 90-minute weekly session for 24 weeks, including 45 minutes of physical activity led by a certified trainer and 45 minutes of health education delivered by trained coaches.\n* Receive one-on-one support from a community health worker to reduce barriers to care and engage with primary care.\n* Complete biometric health screenings and surveys at baseline, 12 weeks, and 24 weeks to assess clinical and behavioral outcomes.\n* Use a smartwatch, blood pressure cuff, and other tools to track progress in real time.\n* Participate in exit focus groups or interviews to share feedback about the intervention.\n* A subset of TWC leaders and interventionists (N=15) will also be interviewed to assess implementation, resource needs, and sustainability.\n\nThis study uses the RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance) framework to assess Reach, Effectiveness, Adoption, Implementation, and Maintenance, and aims to inform scalable strategies for improving CVH among Black men in trusted community settings.",[101,102,28,103,29,104],"High Blood Glucose","High Cholesterol","Blood Sugar; High","Diabetes Type 2","2026-01-21",{"date":107,"type":46},"2026-01-22",{"date":109,"type":46},"2026-01-01",{"date":111,"type":20},"2027-01-01",{"name":113,"class":53},"University of Alabama at Birmingham"]